Bicycle Therapeutics (BCYC) Capital Expenditures (2018 - 2026)
Bicycle Therapeutics posted quarterly Capital Expenditures of $713000.0 for Q1 2026, up 18.05% year-on-year from $604000.0 in Q1 2025, and up 24.22% on a QoQ basis from $574000.0 in Q4 2025.
Bicycle Therapeutics (BCYC) has 9 years of Capital Expenditures data on file, last reported at $713000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 18.05% year-over-year to $713000.0; the trailing twelve-month figure through Mar 2026 stood at $2.5 million (up 34.59% YoY), and the FY2025 full-year result was $2.4 million, up 90.28% from the prior year.
- Capital Expenditures for Q1 2026 stood at $713000.0, up from $574000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $9.8 million in Q2 2022 and bottomed at $12000.0 in Q1 2024.
- The 5-year median for Capital Expenditures is $574000.0 (2025), against an average of $1.5 million.
- The widest annual swing landed in 2022, when Capital Expenditures surged 5630.41%; it then sank 99.43% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $1.4 million in 2022, then sank by 96.48% to $51000.0 in 2023, then soared by 621.57% to $368000.0 in 2024, then surged by 55.98% to $574000.0 in 2025, then gained by 24.22% to $713000.0 in 2026.
- The last three Capital Expenditures figures came in at $713000.0 (Q1 2026), $574000.0 (Q4 2025), and $674000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | 713,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 713,000.00 |
| Mar 31, 2026 | 713,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Dec 31, 2025 | 574,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Sep 30, 2025 | 674,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 498,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Mar 31, 2025 | 604,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Dec 31, 2024 | 368,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Sep 30, 2024 | 435,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Mar 31, 2024 | 12,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Dec 31, 2023 | 51,000.00 |
| Sep 30, 2023 | 502,000.00 |
| Sep 30, 2023 | 502,000.00 |
| Jun 30, 2023 | 277,000.00 |
| Jun 30, 2023 | 277,000.00 |
| Mar 31, 2023 | 2.10 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 1.45 Mn |
| Dec 31, 2022 | 1.45 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Sep 30, 2022 | 2.98 Mn |
| Jun 30, 2022 | 9.80 Mn |
| Jun 30, 2022 | 9.80 Mn |
| Mar 31, 2022 | 4.76 Mn |
| Mar 31, 2022 | 4.76 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 169,000.00 |
| Sep 30, 2021 | 169,000.00 |
| Jun 30, 2021 | 171,000.00 |
| Jun 30, 2021 | 171,000.00 |
| Mar 31, 2021 | 623,000.00 |
| Mar 31, 2021 | 623,000.00 |
| Dec 31, 2020 | 484,000.00 |
| Dec 31, 2020 | 484,000.00 |
| Sep 30, 2020 | 95,000.00 |
| Sep 30, 2020 | 95,000.00 |
| Jun 30, 2020 | 301,000.00 |
| Jun 30, 2020 | 301,000.00 |
| Mar 31, 2020 | 320,000.00 |
| Mar 31, 2020 | 320,000.00 |
| Dec 31, 2019 | 391,000.00 |
| Dec 31, 2019 | 391,000.00 |
| Sep 30, 2019 | 283,000.00 |
| Sep 30, 2019 | 283,000.00 |
| Jun 30, 2019 | 463,000.00 |
| Jun 30, 2019 | 463,000.00 |
| Mar 31, 2019 | 418,000.00 |
| Mar 31, 2019 | 418,000.00 |
| Dec 31, 2018 | 410,000.00 |
| Dec 31, 2018 | 410,000.00 |
| Sep 30, 2018 | 126,000.00 |
| Sep 30, 2018 | 126,000.00 |